SCHEMBL411104

SCHEMBL411104

O=S(=O)(NCCOc1ccccc1)c1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.79
HTT P42858 2/20 0.77
MEN1 O00255 1/20 0.77
KMT2A Q03164 1/20 0.77
NPSR1 Q6W5P4 1/20 0.65
MAPK1 P28482 1/20 0.63
TDP1 Q9NUW8 1/20 0.62
SMN1; SMN2 Q16637 3/20 0.60
LMNA P02545 2/20 0.60
CA12 O43570 1/20 0.60
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
ADRB2 P07550 1/20 0.60
ADRB1 P08588 1/20 0.60
CA9 Q16790 1/20 0.60
KDM4E B2RXH2 1/20 0.59
PKM P14618 1/20 0.59
TSHR P16473 1/20 0.58
MAPT P10636 1/20 0.56
GLRA3 O75311 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1880968 0.95 ALDH1A1 (0.72) ALDH1A1HTTMEN1KMT2ANPSR1
SCHEMBL13889018 0.90 HTT (0.74) ALDH1A1HTTMEN1KMT2ANPSR1
SCHEMBL1876555 0.90 ALDH1A1 (0.71) ALDH1A1HTTMEN1KMT2ANPSR1
SCHEMBL3765016 0.89 HTT (0.72) ALDH1A1HTTMEN1KMT2ANPSR1
SCHEMBL25132140 0.88 HTT (1.00) ALDH1A1HTTMEN1KMT2ANPSR1
SCHEMBL4519542 0.85 HTT (0.71) ALDH1A1HTTMEN1KMT2ANPSR1
SCHEMBL10613964 0.84 HTT (0.66) ALDH1A1HTTMEN1KMT2ANPSR1
SCHEMBL14712382 0.84 NPSR1 (0.67) ALDH1A1HTTMEN1KMT2ANPSR1
SCHEMBL12640166 0.83 ALDH1A1 (1.00) ALDH1A1HTTMEN1KMT2ANPSR1
SCHEMBL23139930 0.82 HTT (0.59) ALDH1A1HTTMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-A1 METHODS OF USING MEK INHIBITORS Exelixis, Inc. (US) 2009-09-23 EP claimed
WO-2008076415-A1 METHODS OF USING MEK INHIBITORS EXELIXIS, INC. (US) 2008-06-26 WO claimed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 US disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 US disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 US disclosed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 US disclosed
US-9174947-B2 c-Met modulators and methods of use Exelixus, Inc. (US) 2015-11-03 US disclosed
US-20140155378-A9 c-Met Modulators and Method of Use EXELIXIS, INC. (US) 2014-06-05 US disclosed
US-20140155396-A1 C-Met Modulators and Method of Use EXELIXIS, INC. 2014-06-05 US disclosed
US-8067436-B2 N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death EXELIXIS, INC. (US) 2011-11-29 US disclosed
US-20110077233-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2011-03-31 US disclosed
US-7579473-B2 N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death EXELIXIS, INC. (US) 2009-08-25 US disclosed
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 US disclosed
EP-1443041-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET ALDH1A1 2072/4885HTT 3792/4885MEN1 1228/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET ALDH1A1 2072/4885HTT 3792/4885MEN1 1228/4885
US-20140155378-A9 c-Met Modulators and Method of Use FLT4, MET, FLT1 ALDH1A1 2578/4885HTT 4089/4885MEN1 1333/4885
US-20140155396-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 ALDH1A1 2578/4885HTT 4089/4885MEN1 1333/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET ALDH1A1 2072/4885HTT 3792/4885MEN1 1228/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET ALDH1A1 2072/4885HTT 3792/4885MEN1 1228/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET ALDH1A1 2072/4885HTT 3792/4885MEN1 1228/4885
US-20090170896-A1 c-Met modulators and methods of use FLT4, MET, FLT1 ALDH1A1 2597/4885HTT 4046/4885MEN1 1410/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 ALDH1A1 2578/4885HTT 4089/4885MEN1 1333/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 ALDH1A1 2578/4885HTT 4089/4885MEN1 1333/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 ALDH1A1 2578/4885HTT 4089/4885MEN1 1333/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET ALDH1A1 2072/4885HTT 3792/4885MEN1 1228/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 ALDH1A1 2597/4885HTT 4046/4885MEN1 1410/4885
US-20110077233-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 ALDH1A1 2578/4885HTT 4089/4885MEN1 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.